«Engineering novel methods of delivering monoclonal
antibodies could be an important approach in the fight
against infection and in unique treatment situations,» said senior author David B. Weiner, PhD, a professor of Pathology and Laboratory Medicine and chair of the Gene Therapy and Vaccine
Program.
iTeos and Adimab LLC are collaborating on the discovery, development and commercialization of multiple,
antibody - based therapeutic
programs, with Adimab using its
antibody discovery and optimization platform to identify fully human therapeutic
antibodies against targets selected by iTeos.